Clesrovimab: Can a monoclonal antibody protect infants from severe RSV?

Written by The Life Science Feed Editorial Team · Published 18 August 2026 · Edited by William Lopes

> Respiratory syncytial virus (RSV) remains a significant cause of hospitalisation and morbidity in infants and young children, particularly those entering their second season of exposure. While initial protection can be offered, the challenge lies in sustaining immunity through subsequent vulnerable periods. The development of novel prophylactic strategies is essential to address this unmet need, as infants' health is at stake.

KEY TAKEAWAYS

- The Pivot: Monoclonal antibodies offer a new approach to passive immunisation against RSV, extending protection beyond the first season.
- The Data: Specific clinical trial data is not yet available for clesrovimab, but the mechanism targets the F protein to prevent viral entry.
- The Action: Clinicians should monitor developments in long-acting monoclonal antibodies for RSV, as these could alter prophylactic strategies for at-risk paediatric populations.

Respiratory syncytial virus is a ubiquitous pathogen, causing annual epidemics of respiratory illness. For most healthy adults and older children, RSV infection presents as a mild cold. But in infants, especially those born prematurely or with underlying cardiac or pulmonary conditions, RSV can lead to severe lower respiratory tract disease, including bronchiolitis and pneumonia, often necessitating hospitalisation and intensive care. The burden on paediatric healthcare systems during peak RSV season is substantial, underscoring the need for effective preventive measures.

Existing strategies for RSV prevention primarily focus on passive immunisation for high-risk infants during their first RSV season. These approaches involve administering antibodies directly to provide temporary protection. But the duration of protection from these agents is limited, and the logistics of monthly injections can be challenging for families and healthcare providers. The need for a longer-acting solution, particularly for children who remain vulnerable into their second RSV season, has driven research into new monoclonal antibodies like clesrovimab.

The Mechanism of Action

Clesrovimab is a monoclonal antibody designed to target the fusion (F) protein of the respiratory syncytial virus. The F protein is highly conserved across RSV strains and is essential for viral entry into host cells. By binding to this protein, clesrovimab aims to neutralise the virus, preventing it from infecting respiratory epithelial cells and thus reducing the risk of severe disease. This mechanism is similar to other monoclonal antibodies developed for RSV, but clesrovimab is engineered for extended half-life, potentially allowing for less frequent dosing.

The extended half-life is a critical feature, as it could provide protection for an entire RSV season with a single dose.

This would represent a significant improvement over current options, which require multiple administrations. Such a simplified regimen could improve adherence and ensure more consistent protection for vulnerable infants, including those who may have missed doses of shorter-acting agents. The goal is to offer broad protection against both RSV-A and RSV-B subtypes, which are both prevalent during seasonal outbreaks.

Addressing the Unmet Need in Paediatric Populations

Infants entering their second RSV season, particularly those with chronic lung disease of prematurity or congenital heart disease, remain at elevated risk for severe RSV outcomes. These children often have compromised respiratory or cardiovascular systems that make them less resilient to viral insults. While their immune systems are maturing, they may still not mount a sufficiently protective response to natural infection, making passive immunisation a valuable strategy. The gaps in paediatric pulmonary research highlight the ongoing challenges in protecting this vulnerable group.

The development of clesrovimab aims to fill this specific gap, offering a prophylactic option for a population that currently has limited choices for sustained protection. The convenience of a single-dose, long-acting agent could also alleviate some of the logistical burdens on families and healthcare systems, potentially leading to higher rates of immunisation. This could translate into fewer hospitalisations and reduced strain on paediatric intensive care units during peak RSV periods. For a comprehensive understanding of paediatric care, the Oxford Handbook of Paediatrics is an invaluable resource.

But the real-world effectiveness of any new prophylactic agent depends on its accessibility and integration into existing healthcare pathways. While the mechanism of action is sound, the practicalities of distribution, cost, and physician uptake will determine its impact. The potential for a single-dose regimen could simplify administration, but it also places a greater emphasis on ensuring that dose is delivered at the optimal time before the RSV season begins. This requires robust public health campaigns and clear clinical guidelines.

The long-term safety profile of extended-half-life monoclonal antibodies in a developing immune system is also a consideration. While these agents are generally well-tolerated, continuous surveillance for any unexpected adverse events will be critical once they are in broader use. The focus remains on preventing severe disease without interfering with the natural development of the infant's own immune response to RSV. The balance between passive protection and active immunity is delicate, and any intervention must respect this biological process.

The potential for clesrovimab to protect children entering their second RSV season represents a significant step forward in paediatric infectious disease prevention. The goal is to reduce the incidence of severe RSV disease, thereby decreasing hospitalisations and improving outcomes for a vulnerable population. The next steps involve rigorous clinical evaluation to confirm efficacy and safety across diverse paediatric cohorts, ensuring that this therapeutic advance translates into tangible benefits for patients.

> **CLINICAL IMPLICATIONS**
>
> The prospect of a long-acting monoclonal antibody like clesrovimab for RSV prophylaxis in infants, particularly those entering their second season, is genuinely compelling. Current options, while effective for specific high-risk groups in their first year, often fall short in providing sustained, convenient protection. A single-dose, seasonal intervention could significantly simplify the immunisation schedule, reducing the burden on both parents and overstretched paediatric clinics.

> Clinicians should view this development as a potential game-changer for managing RSV risk in vulnerable populations. The extended half-life means fewer clinic visits for injections, which directly translates to better adherence and, presumably, better protection rates. This could free up resources currently dedicated to monthly injections, allowing for reallocation to other critical paediatric health initiatives.
> But the real impact will hinge on the breadth of its approval and the cost-effectiveness. If clesrovimab is approved for a wider population of infants, not just the highest-risk groups, it could substantially reduce the overall RSV disease burden. Payers will scrutinise the economic argument, weighing the cost of the antibody against the avoided hospitalisations and intensive care admissions.
> The success of clesrovimab, or any similar agent, will depend on its seamless integration into routine paediatric care. Clear guidelines on patient selection, optimal timing of administration, and robust post-marketing surveillance will be essential. This is not merely about a new drug; it is about reshaping how we protect our youngest patients from a persistent and dangerous respiratory threat.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025;13:25151355241310601. doi:10.1177/25151355241310601
2. 2. Moulia DL, Link-Gelles R, Chu HY, et al. Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(32):508-514. doi:10.15585/mmwr.mm7432a3
3. 3. Paes BA, Manzoni P, Fullarton JR, Rodgers-Gray BS, Carbonell-Estrany X. RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein. Vaccines (Basel). 2026;14(7). doi:10.3390/vaccines14070556
4. 4. Novoa Pizarro JM, Lindemann Tappert BC, Luchsinger Farías VR, Vargas Munita SL. [Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?]. Andes Pediatr. 2023;94(6):672-680. doi:10.32641/andespediatr.v94i6.4861

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com